### **Overview** Concord Biotech Ltd is a leading, R&D-driven biopharmaceutical company based in Gujarat, India, with over 25 years of expertise in fermentation-based technology. The company operates across three core business verticals: **Active Pharmaceutical Ingredients (APIs)**, **Finished Formulations**, and **Contract Development & Manufacturing Organization (CDMO/CRAMS)** services. It has established itself as a global leader in fermentation-based APIs, leveraging deep technical expertise, backward integration, and a vertically integrated manufacturing model to deliver high-quality, niche pharmaceutical products. --- ### **Core Business Segments** #### **1. Active Pharmaceutical Ingredients (APIs)** - **Revenue Contribution:** APIs accounted for **78% of total revenue in FY25** (₹940 crores), aligning with its long-term 80:20 revenue split guidance. - **Product Portfolio:** - Over **30 commercialized fermentation-based APIs** across **immunosuppressants** (e.g., Tacrolimus, Cyclosporine, Sirolimus), **oncology**, **anti-infectives**, and **antifungals** (e.g., Amphotericin B, Micafungin). - Key molecules include Vancomycin, Teicoplanin, Nystatin, and Epirubicin. - **Fermentation Capacity:** Total installed capacity of **1,250 m³** across two dedicated API facilities in **Dholka (450 m³)** and **Limbasi (800 m³)**. - **Backward Integration:** Full control up to **Key Starting Materials (KSMs)**, ensuring supply chain resilience, cost efficiency, and quality assurance. - **Regulatory Approvals:** Facilities approved by **USFDA, EU-GMP, PMDA (Japan), ANVISA (Brazil), MFDS (Korea)**, and others—enabling market access in over 70 countries. - **Global Market Share:** Holds **20–45% volume market share** in five key fermentation-based APIs. - **R&D Pipeline:** Over **10 new API products** in development, targeting commercialization in 5–7 years, with focus on **oncology**, **anti-infectives**, and **antibacterials**. #### **2. Finished Formulations** - **Revenue Contribution:** Contributed **22% of FY25 revenue** (₹260 crores), up from ₹189 crores in FY24. - **Portfolio:** - **Over 100 approved formulation products** across chronic and lifestyle therapies. - Dosage forms include **oral solids (tablets, capsules, suspensions)** and now **injectables (liquid vials, lyophilized powders)**. - Branded products: **Amfoterol™, Caspocon™, Tacrocord™, Conimab™, Unuric™**. - **Therapeutic Areas:** Immunosuppressants, oncology, critical care, nephrology, rheumatology, and anti-infectives. - **Manufacturing:** - **Valthera Facility**: 802 million units/year capacity for oral and liquid formulations. - **New Injectable Facility**: Commissioned in **Q4 FY25**, with capacity for **13 million liquid vials, 12 million dry powder vials, and 2,200 kg lyophilized API/year**. - **Distribution Models:** - **India:** B2B (government/corporate hospitals) and B2C. - **International:** B2B via distributors in the **U.S., Latin America, Middle East, Africa, and Asia**. - **Regulatory Approvals:** Formulation facilities inspected and approved by **USFDA, EU-GMP, PMDA, ANVISA**, etc. - **U.S. Entry:** Received **USFDA approval for Teriflunomide Tablets (7mg, 14mg)** for relapsing multiple sclerosis—a product in a **$908 million global market**, opening a major new growth avenue. #### **3. Contract Development & Manufacturing (CDMO/CRAMS)** - **Commercial Launch:** Initiated **commercial supply under CDMO agreement with a major U.S. customer** in August 2025, marking the start of dedicated revenue. - **Service Offerings:** - Strain improvement, media optimization, process development, scale-up, and commercial manufacturing. - Specialization in **fermentation-based and semi-synthetic APIs**, complex formulations. - **Infrastructure:** - DSIR-certified R&D facility with **170+ scientists**. - Scalable, globally compliant facilities with flexible configurations. - **Growth Catalyst:** Identified as a **medium-term growth engine**, driven by increasing industry interest in diversifying supply chains (e.g., **China-plus-one**, **BioSecure Act** tailwinds). - **Partnerships:** Actively engaging **innovator and generic pharma companies**, with multiple projects in CDMO pipeline. --- ### **Strategic Expansion & Globalization** #### **U.S. Market Entry** - **Stellon Biotech Inc.:** Wholly-owned U.S. subsidiary incorporated in 2025 to manage **end-to-end commercial operations** for products in the U.S., including marketing, distribution, warehousing, and regulatory compliance. - **Purpose:** To strengthen direct control over commercialization, increase value capture, and improve U.S. market penetration. #### **Domestic Growth** - **Concord Lifegen Limited:** Wholly-owned Indian subsidiary to enhance **domestic sales, marketing, and distribution capabilities** in the Indian pharmaceutical market. - **Sales Force:** Over **200 dedicated professionals** across India, focused on government and corporate hospitals. #### **Joint Venture** - **Concord Biotech Japan K.K.:** A strategic joint venture to strengthen presence in the **Japanese market**. --- ### **R&D and Innovation** - **R&D Team:** **180+ scientists** in integrated API and formulations R&D. - **Facilities:** In-house **strain isolation, mutation, enhancement**, pilot plants, and advanced analytical labs. - **Regulatory Filings:** - Over **135 API Drug Master Files (DMFs)** filed globally. - **7 ANDAs approved by USFDA**, with multiple formulations and drugs under review. - **Pipeline:** - More than **10 new fermentation-based APIs** in development for **oncology, anti-infectives, and antifungals**. - Focus on **patent-expired molecules** (e.g., Tacrolimus, Cyclosporine, Everolimus) for generic formulation development. --- ### **Manufacturing & Sustainability** - **Four Advanced Manufacturing Units in Gujarat:** 1. **API – Dholka (Unit I)** 2. **API – Limbasi (Unit II)** 3. **Oral Formulations – Valthera (Unit III)** 4. **Injectable Formulations – Valthera (Unit IV)** - **Integrated Model:** End-to-end control from **R&D to finished dosages**, reducing time-to-market and ensuring quality. - **Sustainability Initiatives:** - **26% equity stake in Cleanmax Everglades**, securing **6.6 MW wind + 3.3 MW solar** power for the Dholka plant. - **Zero Liquid Discharge (ZLD)** systems across facilities. - **EcoVadis Bronze Rating** for sustainability practices. --- ### **Strategic Investments & Partnerships** - **Palvella Therapeutics Inc.:** Strategic investment in a U.S.-based biotech firm developing **QTORIN**, a topical therapy for rare genetic skin diseases. - **Purpose:** Establish a **long-term manufacturing and commercialization partnership**, expanding Concord’s footprint in **rare and specialty dermatology** therapeutics. --- ### **Regulatory & Market Presence** - **Global Reach:** Serves **250+ customers across 70+ countries**. - **Regulatory Compliance:** Facilities regularly inspected and approved by **USFDA, EMA, PMDA, ANVISA, EU-GMP, WHO**, among others. - **PLI Scheme Beneficiary:** Approved under the Indian government’s Production Linked Incentive (PLI) scheme for fermentation-based APIs. --- ### **Key Competitive Advantages** 1. **High Barriers to Entry:** - Requires specialized **microbiological expertise**, **capital investment (~₹200–300 crores per unit)**, **long development timelines**, and **regulatory validation**. 2. **Full Vertical Integration:** - Only Indian company offering **KSM → API → Finished Dosage** integration for fermentation-based immunosuppressants. 3. **Global Regulatory Credibility:** - Proven ability to meet stringent standards in **U.S., EU, Japan, and Brazil**. 4. **Diversified Portfolio & Customer Base:** - Reduced customer concentration (Top 10 down from **60% in FY20 to 42% in FY25**). - Added **118 new customers in FY25** across segments. 5. **Sustainable, Scalable Manufacturing:** - Flexible plant configurations, ZLD systems, renewable energy integration. --- ### **Recent Milestones (2025)** - Commercial production commenced at **Valthera Injectable Facility (Q4 FY25)**. - U.S. FDA approval for **Teriflunomide Tablets**. - Revenue growth of **38% YoY** in formulations business (FY25). - Successful **CDMO commercial launch** with U.S. client. - Incorporation of **Stellon Biotech (U.S.)** and **Concord Lifegen (India)**. - Strategic CDMO discussions underway with multiple global innovator and generic companies.